Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
ClinicalTrials.gov processed this data on October 23, 2024. Link to the current ClinicalTrials.gov record.Recruitment Status
RECRUITING (See Contacts and Locations)Verified October 2024 by Janssen Research & Development, LLC
Sponsor
Janssen Research & Development, LLCInformation Provided by (Responsible Party)
Janssen Research & Development, LLCClinicaltrials.gov Identifier
NCT04899336Other Study ID Numbers: CR109000
First Submitted: May 21, 2021
First Posted: May 24, 2021
Last Update Posted: October 24, 2024
Last Verified: October 2024
History of Changes
Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.
Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.
Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.
For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.
See also the Web Policies and Notices for the NIH web site.
Study Description
Invasive extraintestinal pathogenic Escherichia coli disease (IED) is defined as an acute illness consistent with systemic bacterial infection, which is microbiologically confirmed either by the isolation and identification of Escherichia coli (E. coli) from blood or any other sterile body sites, or by the isolation and identification of E. coli from urine in a participant with urosepsis and no other identifiable source of infection. ExPEC9V (JNJ-78901563, primary compound number: VAC52416) is a 9-valent vaccine candidate in development for active immunization for the prevention of IED in adults 60 years of age and older. Although IED affects all ages, adults aged greater than or equal to (>=) 60 years have an increased risk of developing IED, including bacteremia and sepsis, which can be community-acquired, hospital-acquired or healthcare associated. As the mechanism of action of conjugate vaccines in the prevention of invasive disease is not expected to be affected by antibiotic resistance mechanisms, that is, resistance mechanisms are not linked to O-polysaccharide structures, the sponsor has no reason to expect a difference in outcome of efficacy between antimicrobial-resistant and susceptible O-serotypes. This study incorporates an inferentially seamless group-sequential design. This study consists of a Screening Phase (selected screening procedures may be performed up to 8 days prior to vaccination on Day 1), Randomization, Vaccination Phase (Day 1) and Follow-up Phase (up to 4 years post-vaccination). The total study duration is approximately up to 6 years 9 months. Key safety assessments include serious adverse events (SAEs), solicited and unsolicited adverse events (AEs), physical examination, and vital signs.Condition or Disease | Intervention/Treatment |
---|---|
|
|
Study Design
Study Type | Interventional |
---|---|
Anticipated Enrollment | 19800 participants |
Design Allocation | Randomized |
Interventional Model | Parallel Assignment |
Masking | Double |
Primary Purpose | Prevention |
Official Title | Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years |
Study Start Date | June 30, 2021 |
Anticipated Primary Completion Date | May 19, 2025 |
Anticipated Study Completion Date | June 29, 2029 |
Groups and Cohorts
Group/ Cohort | Intervention/ Treatment |
---|---|
|
|
|
|
Outcome Measures
Primary Outcome Measures
- Number of Participants with First Invasive Extraintestinal Pathogenic E.coli Disease (IED) Event with Microbiological Confirmation in Blood or Other Sterile Sites Caused by 9-valent Extraintestinal Pathogenic E. coli Vaccine (ExPEC9V) O-serotypes [Up to 4 years] Number of participants with first IED event with microbiological confirmation in blood or other sterile sites, excluding IED cases with microbiological confirmation from urine only, caused by ExPEC9V O-serotypes will be reported.
Secondary Outcome Measures
- Number of Participants with First IED Event with Microbiological Confirmation in Blood, Other Sterile Sites, or Urine, Caused by ExPEC9V O-serotypes [Up to 4 years] Number of participants with first IED event, with microbiological confirmation in blood, other sterile sites, or urine, caused by ExPEC9V O-serotypes will be reported.
- Number of All IEDs (Including Multiple IEDs per Participant) Caused by ExPEC9V O-serotypes [Up to 4 years] Number of all IEDs (including multiple IEDs per participant) caused by ExPEC9V O-serotypes will be reported.
- Number of Participants with First Hospitalized IED Event Caused by ExPEC9V O-serotypes [Up to 4 years] Number of participants with first hospitalized IED event caused by ExPEC9V O-serotypes will be reported.
- Number of Participants with First IED Event Meeting Criteria for Sepsis Caused by ExPEC9V O-serotypes [Up to 4 years] Number of participants with first IED event meeting criteria for sepsis caused by ExPEC9V O-serotypes will be reported.
- Number of Participants with First Bacteremic IED Event Caused by ExPEC9V O-serotypes [Up to 4 years] Number of participants with first bacteremic IED event caused by ExPEC9V O-serotypes will be reported.
- Number of Participants with First Pyelonephritis Event Caused by ExPEC9V O-serotypes [Up to 4 years] Number of participants with first pyelonephritis event caused by ExPEC9V O-serotypes will be reported.
- Number of Participants with First Urinary Tract Infection (UTI) Event Caused by ExPEC9V O-serotypes [Up to 3 years] Number of participants with first UTI event caused by ExPEC9V O-serotypes will be reported.
- Number of All UTIs (Including Multiple UTIs per Participant) Caused by ExPEC9V O-serotypes [Up to 3 years] Number of all UTIs (including multiple UTIs per participant) caused by ExPEC9V O-serotypes will be reported.
- Number of Participants with First IED Event Caused by Escherichia coli (E.coli) [Up to 4 years] Number of participants with first IED event caused by E.coli will be reported.
- Number of Participants with First Pyelonephritis Event caused By E.coli [Up to 4 years] Number of participants with first pyelonephritis event caused by E.coli will be reported.
- Number of Participants with First UTI Event caused by E.coli [Up to 3 years] Number of participants with first UTI event caused by E.coli will be reported.
- Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex Electrochemiluminescent (ECL)-based Immunoassay [Up to 4 years] Antibody titers to vaccine O-serotype antigens as determined by multiplex ECL-based immunoassay will be reported.
- Antibody Titers to Genetically Detoxified Form of Exotoxin A Derived from Pseudomonas Aeruginosa (EPA) as Determined by Multiplex ECL-based Immunoassay [Up to 4 years] Antibody titers to EPA as determined by multiplex ECL-based immunoassay will be reported.
- Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex Opsonophagocytic Assay (MOPA) [Up to 4 years] Antibody titers to vaccine O-serotype antigens as determined by MOPA will be reported.
- Number of Participants with Solicited Local Adverse Events (AEs) [Up to Day 15 (until 14 days post-vaccination)] Number of participants with solicited local AEs will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs are pre-defined local (at the injection site) AEs. Participants will be asked to note in the diary occurrences of injection site pain/tenderness, erythema and swelling at the study vaccine injection site daily for 14 days post-vaccination (day of vaccination and the subsequent 14 days).
- Number of Participants with Solicited Systemic AEs [Up to Day 15 (until 14 days post-vaccination)] Number of participants with solicited systemic AEs will be reported. Participants will be instructed on how to record daily temperature using a thermometer and also instructed to note signs and symptoms in the diary on a daily basis for 14 days post-vaccination (day of vaccination and the subsequent 14 days). Solicited systemic AEs are fatigue, headache, nausea, and myalgia.
- Number of Participants with Unsolicited AEs [Up to Day 30 (until 29 days post-vaccination)] Number of participants with unsolicited AEs will be reported. Unsolicited AEs are all AEs for which the participant is not specifically questioned in the participant diary.
- Number of Participants with Serious Adverse Events (SAEs) [Up to 181 days] A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.
- Number of Participants with SAEs Related to Study Vaccine or Study Procedures [Up to 4 years] A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important. Participants with SAEs related to study procedures or vaccines will be reported in this outcome measure.
- Short Form-36 (SF-36) Total Scores [Up to 4 years] The SF-36 is a 36-item questionnaire with a recall period for all items of 1 week. The SF 36 version 2 includes 8 domains that measure physical functioning, role limitations due to physical health problems, bodily pain, general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE) and mental health (MH). The 8 domains can be aggregated into 2 summary scales that reflect physical and mental health: a physical component summary (PCS) and a mental component summary (MCS). Responses to all items are rated on a 3-, 5- or 6-point Likert scale. The scores range from 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).
- European Quality of Life (EuroQol) 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Scores [Up to 4 years] The EQ-5D-5L is a standardized measure of health status. It is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
- Change from Baseline in Frailty Index [Baseline to 4 years] Frailty will be assessed at baseline based on Short Physical Performance Battery (SPPB) score and will be calculated using participants self-reported information regarding health status (components of SF-36 and EQ-5D), and baseline health conditions collected through medical conditions of interest. The specific medical conditions of interest used for the calculation of the frailty index score will include: diabetes mellitus, history of myocardial infarction, congestive heart failure, hypertension, history of cerebrovascular disease (sequelae of stroke), chronic obstructive pulmonary disease (COPD), cancer, osteoarthritis or rheumatoid arthritis, gastric or duodenal ulcer, long term disability or handicap, hearing problems, migraine, cataract, and glaucoma. Total Frailty Index, ranging from 0 (not frail or best possible score) to 43 (frail or worst possible score), will be calculated as accumulation of individual's deficits.
- Medical Resource Utilization (MRU) for IED Events Caused by ExPEC9V O-Serotype [Up to Day 366 Post-IED] MRU for IED events caused by ExPEC9V O-serotype will be reported.
- MRU for UTI Events Caused by ExPEC9V O-Serotype [Up to Day 29 Post-UTI] MRU for UTI events caused by ExPEC9V O-serotype (for immunogenicity subset only that is for participants from selected study sites who have given informed consent prior to randomization for additional immunogenicity assessments) will be reported.
- MRU for Acute Bacterial Prostatitis (ABP) Events Caused by ExPEC9V O-Serotype [Up to Day 29 Post-ABP] Medical resource utilization for ABP events caused by ExPEC9V O-serotype (for immunogenicity subset only that is for participants from selected study sites who have given informed consent prior to randomization for additional immunogenicity assessments) will be reported.
- Number of Participants with the Hospitalization for IED or, UTI, or ABP Events Caused by ExPEC9V O-Serotype [Up to 4 years] Number of participants with hospitalization for IED or, UTI, or ABP events caused by ExPEC9V O-serotype will be reported.
- Length of Stay in Hospital for IED, UTI, or ABP Events Caused by ExPEC9V O-Serotype [Up to 4 years] Length of stay in hospital for IED, UTI, or ABP events caused by ExPEC9V O-serotype will be reported.
- Number of Participants with the Intensive Care Unit (ICU) Hospitalization for IED or UTI or ABP Events Caused by ExPEC9V O-Serotype [Up to 3 months post clinical event] Number of participants with ICU hospitalization for IED or UTI or ABP events caused by ExPEC9V O-serotype will be reported.
- Length of ICU Stay in Hospital for IED, UTI, or ABP Events Caused by ExPEC9V O-Serotype [Up to 3 months post clinical event] Length of ICU stay in hospital for IED, UTI, or ABP events caused by ExPEC9V O-serotype will be reported.
- Number of Participants with IED-related and All-cause Mortality [Up to 4 years] Number of participants with IED-related and all-cause mortality will be reported.
Eligibility Criteria
Ages Eligible for Study | 60 Years and Older (Adult, Older Adult) |
---|---|
Sexes Eligible for Study | All |
Accepts Healthy Volunteers | Yes |
Inclusion Criteria |
|
Exclusion Criteria |
|
Contacts and Locations
Sponsors and Collaborators | Janssen Research & Development, LLC |
---|---|
Locations |
|
Investigators |
More Information
Additional Relevant MeSH Terms
- Urinary Tract Infections
- Escherichia coli Infections
- Infections
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Enterobacteriaceae Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses